What to Know About OrbiMed’s $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
On June 22, 2026, Orbimed Advisors, a 10% Owner of Enliven Therapeutics, Inc. (NASDAQ:ELVN), disclosed the indirect sale of 860,123 shares for a total transaction value of approximately $39.0 million, as reported in the SEC Form 4 filing. Transaction summary Transaction value based on SEC Form 4 weighted average purchase price ($45.36); post-transaction value based…
